Related Experiment Video

Updated: Jul 14, 2025

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

9.7K

[Advances in targeted delivery of proteolysis targeting chimeras in cancer therapy]

Xiaobo Wu1,2, Jie Zhao1,2, Yuan Gao2

  • 1School of Materials Science and Engineering, Central South University of Forestry and Technology, Changsha 410004, Hunan, China.

Sheng Wu Gong Cheng Xue Bao = Chinese Journal of Biotechnology
|October 8, 2023
PubMed

Insights

Proteolysis targeting chimeras (PROTAC) offer a novel strategy for cancer treatment by degrading oncogenic proteins. Targeted delivery systems enhance PROTAC efficacy, selectivity, and safety for improved therapeutic outcomes.

Area of Science:

  • Oncology
  • Medicinal Chemistry
  • Drug Delivery

Background:

  • Traditional small-molecule anticancer drugs face challenges with "undruggable" oncogenic proteins.
  • Proteolysis targeting chimeras (PROTAC) represent a promising therapeutic strategy for targeted protein degradation in cancer.

Conclusions:

  • PROTAC-based therapies offer a versatile approach to cancer treatment through targeted protein degradation.
  • Advanced delivery systems are crucial for maximizing PROTAC therapeutic potential and patient safety.
  • Further research into PROTAC druggability is warranted to fully realize their clinical application.
Keywords:
anticancer drugscancerprotein degradesproteolysis targeting chimerastargeted delivery

More Related Videos

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes07:22

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

3.5K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
544